However, since MACROD2-low expression was associated with poor DFS in the subgroup of stage III colon cancer patients who received 5-FU-based adjuvant chemotherapy, two separate models were built for stage II and stage III colon cancers. The gene discussed is MACROD2; the disease is colonic neoplasm.